Skip to main content

Doptelet News

Sobi Announces U.S. Food and Drug Administration Approves Doptelet (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)

WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) – Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (F...

Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)

DURHAM, N.C., June 27, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases wh...

FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure

May 21, 2018 – The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Idiopathic (Immune) Thrombocytopenic Purpura

Doptelet patient information at Drugs.com